Testing momelotinib plus luspatercept for transfusion-dependent myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a combination of two drugs, momelotinib and luspatercept, for people with myelofibrosis who need regular red blood cell transfusions. The goal is to see if the combination can reduce transfusion needs and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of myelofibrosis (primary or after other blood cancers).
- You have high-risk, intermediate-2, or intermediate-1 myelofibrosis (your doctor can explain this).
- You need regular red blood cell transfusions – at least 4 units in the past 8 weeks, or your hemoglobin is below 8 g/dL at least twice, one week apart.
- You have either not used JAK inhibitors before, or you've used ruxolitinib or fedratinib for at least 90 days (or at least 28 days if you needed transfusions or had bad side effects).
- You have not had your spleen removed, and you don't have serious heart, liver, kidney, bleeding, or other active cancer issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This study tests a new drug called LY5830966 for people with myelofibrosis whose disease has not responded to or has returned after treatment with a type I JAK2 inhibitor. The drug aims to help reduce symptoms and improve outcomes.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This trial combines two drugs, bomedemstat and momelotinib, to treat myelofibrosis, a rare blood cancer. It aims to see if the combination helps improve blood counts and reduce symptoms when momelotinib alone isn't working well enough.
This trial compares two oral drugs, momelotinib and ruxolitinib, for people with myelofibrosis who have low blood cell counts. Both drugs aim to reduce an enlarged spleen and improve symptoms, and this study will see which one works better and with fewer side effects.
This trial tests whether the drug momelotinib, given before and after a stem cell transplant (also called a bone marrow transplant), can help people with myelofibrosis. The hope is that it will make the transplant safer and more effective.
Hear when a new Primary Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.